Exchange: NASDAQ·Updated 07:50 PM EDT
CGTX logo

CGTX Cognition Therapeutics Inc

$1.03
$0.01
(0.98%)
Today
Closed $1.03
$0.02
(1.94%)
After Hours
Reported EarningsAug 6
Mkt Cap$97M
Vol294,605.00

About CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
47

Neutral Sentiment

How do you feel about CGTX?

Advertisement|Remove ads.